Valuation dashboard for Minerva Neurosciences, Inc. (NERV) with P/E N/A, P/B -0.78, EV/EBITDA -0.46 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $3.48, NERV has negative trailing earnings (P/E not meaningful) and an ROE of 250.02%. Market capitalisation stands at $162M.
Balance sheet quality for NERV: current ratio of 36.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -0.78 |
| EV / EBITDA | -0.46 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NERV | Minerva Neurosciences, Inc. | $162M | 250.0% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $3.48 |
| Market Cap | $162M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 250.02% |
| Return on Invested Capital | -38.56% |
| Return on Assets | -414.72% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CLGN · CVKD · ENLV · KLTO · NRSN · NRXS · RLYB
Explore sector: Healthcare · Biotechnology
More sections of NERV: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks